NPJ vaccines.
Publisher:
Springer Nature in partnership with the Sealy Center for Vaccine Development,
Country: England
Language: English
Author(s):
Sealy Center for Vaccine Development,
Start Year:2016 -
ISSN:
2059-0105 (Electronic)
2059-0105 (Linking)
2059-0105 (Linking)
Impact Factor
9.2
2022
| NLM ID: | 101699863 |
| (OCoLC): | 947095167 |
| LCCN: | 2016247800 |
| Classification: | W1 |
Multicomponent gold nano-glycoconjugate as a highly immunogenic and protective platform against Burkholderia mallei. Burkholderia mallei (Bm) is a facultative intracellular pathogen and the etiological agent of glanders, a highly infectious zoonotic disease occurring in equines and humans. The intrinsic resistance to antibiotics, lack of specific therapy, high mortality, and history as a biothreat agent, prompt the need of a safe and effective vaccine. However, the limited knowledge of protective Bm-specific antigens has hampered the development of a vaccine. Further, the use of antigen-delivery systems that enhance antigen immunogenicity and elicit robust antigen-specific immune responses has been limited a...
Protection from Hendra virus infection with Canarypox recombinant vaccine. Hendra virus (HeV) is an emerging zoonotic pathogen, which causes severe respiratory illness and encephalitis in humans and horses. Since its first appearance in 1994, spillovers of HeV from its natural reservoir fruit bats occur on almost an annual basis. The high mortality rate in both humans and horses and the wide-ranging reservoir distribution are making HeV a serious public health problem, especially for people exposed to sick horses. This study has aimed to develop an efficient low-cost HeV vaccine for horses based on Canarypox recombinant vector expressing HeV glycoproteins, attachment...